MedAdvisor (ASX:MDR) - Cotización, noticias y análisis

Resumen de acción MDR

MedAdvisor Limited, junto con sus filiales, ofrece soluciones de compromiso con el paciente basadas en la farmacia en Australia, Nueva Zelanda, Estados Unidos y Reino Unido.

Acerca de la empresa

MDR fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	4/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Recompensas

Cotiza un 37.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 101.74%

Los analistas coinciden en que el precio de las acciones subirá un 39.1%

Análisis de riesgos

No se han detectado riesgos en MDR a partir de nuestros controles de riesgos.

Competidores de MedAdvisor Limited

Mach7 Technologies

ASX:M7T

AU$172.5m

Beamtree Holdings

ASX:BMT

AU$54.6m

Volpara Health Technologies

ASX:VHT

AU$290.0m

Cogstate

ASX:CGS

AU$234.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for MedAdvisor
Historical stock prices
Current Share Price	AU$0.29
52 Week High	AU$0.34
52 Week Low	AU$0.16
Beta	0.61
1 Month Change	7.27%
3 Month Change	1.72%
1 Year Change	25.53%
3 Year Change	-6.35%
5 Year Change	-29.76%
Change since IPO	-18.96%

Noticias y actualizaciones recientes

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Apr 24

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Mar 20

Recent updates

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Nov 09

Is MedAdvisor (ASX:MDR) A Risky Investment?

Oct 11

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

Mar 08

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

Feb 10

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

Jan 18

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

Dec 22

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

Dec 18

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

Nov 22

Rentabilidad de los accionistas

	MDR	AU Healthcare Services	Mercado AU
7D	13.5%	5.9%	0.03%
1Y	25.5%	63.1%	4.2%

Rentabilidad vs. Industria: MDR obtuvo unos resultados inferiores a los del sector Australian Healthcare Services , que el año pasado arrojó un rendimiento del 52.4%.

Rentabilidad vs. Mercado: MDR superó al mercado Australian, que obtuvo un rendimiento del 3.9% el año pasado.

Volatilidad de los precios

Is MDR's price volatile compared to industry and market?
MDR volatility
MDR Average Weekly Movement	9.4%
Healthcare Services Industry Average Movement	8.0%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.7%
10% least volatile stocks in AU Market	3.5%

Precio estable de las acciones: MDR no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de MDR (9%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2010	n/a	Rick Ratliff	www.medadvisorsolutions.com

MedAdvisor Limited, junto con sus filiales, ofrece soluciones de compromiso con el paciente impulsadas por la farmacia en Australia, Nueva Zelanda, Estados Unidos y Reino Unido. La empresa ofrece MedAdvisor, una extensión de la farmacia, que permite al paciente pedir recetas repetidas y programar vacunaciones, etc.; y THRiV, una plataforma inteligente omnicanal de gestión de pacientes, que permite el compromiso individualizado del paciente a través de la farmacia comunitaria. MedAdvisor Limited se constituyó en 2010 y tiene su sede en Camberwell (Australia).

Resumen de fundamentos de MedAdvisor Limited

¿Cómo se comparan los beneficios e ingresos de MedAdvisor con su capitalización de mercado?
Estadísticas fundamentales de MDR
Capitalización bursátil	AU$162.30m
Beneficios(TTM)	-AU$9.03m
Ingresos (TTM)	AU$109.43m

1.5x

Ratio precio-ventas (PS)

-18.0x

Ratio precio-beneficio (PE)

¿Está MDR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de MDR
Ingresos	AU$109.43m
Coste de los ingresos	AU$93.81m
Beneficio bruto	AU$15.62m
Otros gastos	AU$24.65m
Beneficios	-AU$9.03m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.016
Margen bruto	14.27%
Margen de beneficio neto	-8.25%
Ratio deuda/patrimonio	21.5%

¿Cómo se ha desempeñado MDR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción MDR

Recompensas

Análisis de riesgos

Competidores de MedAdvisor Limited

ASX:M7T

AU$172.5m

ASX:BMT

AU$54.6m

ASX:VHT

AU$290.0m

ASX:CGS

AU$234.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Recent updates

Consensus EPS estimates fall by 11%, revenue upgraded

Why Investors Shouldn't Be Surprised By MedAdvisor Limited's (ASX:MDR) Low P/S

Are Investors Undervaluing MedAdvisor Limited (ASX:MDR) By 44%?

Forecast breakeven date pushed back to 2026

New minor risk - Profitability

Now 24% overvalued after recent price rise

Consensus estimates of losses per share improve by 33%

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Non-Executive Director recently bought AU$1.2m worth of stock

MedAdvisor Limited, Annual General Meeting, Nov 28, 2023

Consensus estimates of losses per share improve by 32%

Full year 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 50%

MedAdvisor Limited Announces Board Changes

Health Check: How Prudently Does MedAdvisor (ASX:MDR) Use Debt?

Consensus EPS estimates fall by 80%, revenue upgraded

First half 2023 earnings released: EPS: AU$0.009 (vs AU$0.02 loss in 1H 2022)

Price target increased to AU$0.40

MedAdvisor Limited Provides Revenue Guidance for the First Half of the Fiscal Year 2023

MedAdvisor Limited Appoints Kevin Hutchinson as Director

Less than half of directors are independent

MedAdvisor Limited to Report Q1, 2023 Results on Oct 28, 2022

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited, Annual General Meeting, Nov 30, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

MedAdvisor Limited (ASX:MDR) entered a binding agreement to acquire GuildLink Pty Ltd from Guild Group Holdings Limited for AUD 8 million.

MedAdvisor Limited Announces Executive Changes

MedAdvisor (ASX:MDR) Is Carrying A Fair Bit Of Debt

MedAdvisor Limited Announces Change of Managing Director

Price target decreased to AU$0.40

No longer forecast to breakeven

Less than half of directors are independent

MedAdvisor Limited Announces Retirement of Robert Read as CEO

Consensus forecasts updated

MedAdvisor Limited Announces Board Changes

MedAdvisor Limited to Report First Half, 2022 Results on Feb 25, 2022

MedAdvisor Limited Appoints Raeann Grossman to the Board as A Non-Executive Director

Independent Non-Executive Director Peter Bennetto has left the company

Non-Executive Director recently sold AU$2.5m worth of stock

Increases to MedAdvisor Limited's (ASX:MDR) CEO Compensation Might Cool off for now

Is MedAdvisor (ASX:MDR) A Risky Investment?

Less than half of directors are independent

Full year 2021 earnings released

Non-Executive Director has left the company

MedAdvisor Limited announced that it has received AUD 5.25 million in funding

New 90-day low: AU$0.34

Is MedAdvisor (ASX:MDR) Using Too Much Debt?

First half 2021 earnings released: AU$0.029 loss per share (vs AU$0.024 loss in 1H 2020)

MedAdvisor Limited to Report First Half, 2021 Results on Feb 25, 2021

MedAdvisor (ASX:MDR) Shareholders Have Enjoyed A 41% Share Price Gain

What Can We Make Of MedAdvisor's (ASX:MDR) CEO Compensation?

New 90-day low: AU$0.34

Non-Executive Chairman of the Board recently bought AU$70k worth of stock

The Non-Executive Chairman of the Board of MedAdvisor Limited (ASX:MDR), Christopher Ridd, Just Bought A Few More Shares

MedAdvisor Limited Signs an Additional One-Year Deal with A Major Global Pharmaceutical Company

What Kind Of Investors Own Most Of MedAdvisor Limited (ASX:MDR)?

New 90-day low: AU$0.36

Here's Why We're Not Too Worried About MedAdvisor's (ASX:MDR) Cash Burn Situation

New 90-day low: AU$0.39